Zimmer Biomet (ZBH) Stock Looks Cheap Relative To Fair Value

Zimmer Biomet Holdings stock has had a difficult run over the past few years, yet the current valuation checks still lean toward the shares being cheap rather than expensive. The question for you is whether a weak long term share price record is masking an opportunity or simply reflecting the underlying business reality.

• Over the past 5 years, Zimmer Biomet Holdings has declined about 31.4%, which suggests investors have been cautious on the stock for a sustained period.
• Recent leadership promotions and a reshaped Americas structure may support better commercial execution. However, any disruption from management change or slower than expected transformation could weigh on how the market prices the business.
• The broader valuation work points to an undervalued setup, with the company screening as cheap on most checks and a high value score of 5, which suggests the current price builds in restrained expectations.

The issue now is whether Zimmer Biomet Holdings is simply a lowly rated stock for good reason or a mispriced opportunity that could appeal to value focused investors.

Scan beyond Zimmer Biomet Holdings and explore other value ideas with similar pressure on long term returns inside the curated 31 high quality undervalued stocks.

Is Zimmer Biomet Holdings a Bargain on Earnings?

The P/E ratio is a practical way to gauge what you are paying today for each dollar of Zimmer Biomet Holdings earnings. Zimmer Biomet trades on about 22.1x earnings, which sits below both the Medical Equipment industry average of roughly 24.7x and a broader peer group closer to 34.6x.

The fair P/E ratio implied by the valuation work is about 28.9x. That is materially above the current multiple, which indicates the market is pricing Zimmer Biomet at a discount relative to what its earnings profile, sector, size and risk characteristics might usually command. Despite recent leadership changes that could influence sentiment, the current P/E still reflects more cautious pricing than either the industry or the model would suggest.

On the P/E multiple alone, Zimmer Biomet stock appears undervalued compared with both sector norms and the modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Zimmer Biomet Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Zimmer Biomet Holdings valuation puzzle leaves off by spelling out which paths for future growth, profitability and earnings would need to unfold for the stock to be worth materially more or less than today’s price, based on scenarios that live on the Community page. Each narrative ties a possible fair value to a specific storyline about Zimmer Biomet Holdings' potential catalysts and key risks so you can track which version of events appears to be emerging over time.

Share a narrative on Zimmer Biomet Holdings' leadership reshuffle and commercial transformation. Present a clear, number-driven case on whether this reset aligns with the valuation signals you see today.

Be one of the first voices in the Simply Wall St community to set out a structured view on Zimmer Biomet Holdings' path from here and observe how your thesis compares as fresh results and updates are released.

Do you think there's more to the story for Zimmer Biomet Holdings? Head over to our Community to see what others are saying!

The Bottom Line

Zimmer Biomet Holdings screens as undervalued on market multiples, which suggests investor expectations remain muted despite the current earnings profile. The discount only really closes if the refreshed leadership structure can translate into steadier execution and more consistent profitability. For now, the gap between what the numbers imply and how the market prices the stock largely comes down to one question: does the reshaped commercial model earn back sufficient confidence for the P/E to move closer to sector norms, or is the lower rating a reflection of ongoing execution risk?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com